[Optimal timing of insulin detemir injection in patients with type 1 diabetes and poor metabolic control]

What Was Tested

The paper reports a study of Insulin Detemir, published as a randomized controlled trial.

To compare different administration times of insulin detemir (IDet) in patients with type 1 diabetes and poor metabolic control.

Who Took Part

According to the abstract, 39 people were involved.

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

Whenever target glycemia levels were not reached, the regimen was switched to insulin therapy with two injections (IDet-12h).

How the Study Was Run

The design is described as randomized.

Because people in this Insulin Detemir study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

This 24-week open study included 39 people with type 1 diabetes mellitus (DM) randomized to one injection of IDet before lunch (mean 14.24 + or - 00.36 (+ or - SD) h) or at bedtime (23.19 + or - 0.42 h).

Insulin aspart was used before main meals.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Drug Monitoring, Eating and Glycated Hemoglobin.

What This Means in Plain Language

The paper is a randomized study of Insulin Detemir in 39 people.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion), a journal based in Spain.

More context: the Insulin Detemir compound page, all human trials.